Vaxart Future Growth

Future criteria checks 2/6

Vaxart is forecast to grow earnings and revenue by 22.6% and 45.2% per annum respectively while EPS is expected to grow by 12.7% per annum.

Key information

22.6%

Earnings growth rate

12.7%

EPS growth rate

Biotechs earnings growth28.3%
Revenue growth rate45.2%
Future return on equityn/a
Analyst coverage

Low

Last updated19 Nov 2024

Recent future growth updates

Recent updates

Investors Give Vaxart, Inc. (NASDAQ:VXRT) Shares A 29% Hiding

Nov 16
Investors Give Vaxart, Inc. (NASDAQ:VXRT) Shares A 29% Hiding

There's Reason For Concern Over Vaxart, Inc.'s (NASDAQ:VXRT) Massive 39% Price Jump

Aug 20
There's Reason For Concern Over Vaxart, Inc.'s (NASDAQ:VXRT) Massive 39% Price Jump

An Intrinsic Calculation For Vaxart, Inc. (NASDAQ:VXRT) Suggests It's 26% Undervalued

Jun 15
An Intrinsic Calculation For Vaxart, Inc. (NASDAQ:VXRT) Suggests It's 26% Undervalued

Here's Why Vaxart (NASDAQ:VXRT) Must Use Its Cash Wisely

Nov 08
Here's Why Vaxart (NASDAQ:VXRT) Must Use Its Cash Wisely

Vaxart (NASDAQ:VXRT) Will Have To Spend Its Cash Wisely

Jun 30
Vaxart (NASDAQ:VXRT) Will Have To Spend Its Cash Wisely

Vaxart: The Market Still Isn't Buying Oral Vaccine Thesis

Sep 09

Ray Stapleton joins Vaxart as CTO

Aug 31

Vaxart shareholders approve proposal to increase number of shares

Aug 05

Vaxart continues to lobby shareholders to vote to increase number of shares

Jul 29

Vaxart oral COVID-19 pill vaccine candidate induces long-lasting antibodies against SARS-CoV-2

Jul 20

Vaxart says recent CRO agreement 'may be integral' to oral COVID vaccine success

Jul 07

Vaxart: A Unique Vaccine Concern

Jun 14

Vaxart: A Speculative Biotech With Potential As Covid-19 Play And Oral Vaccine Platform

Feb 26

Vaxart: Investment Case For An Oral COVID Vaccine Not So Hard To Swallow

Dec 09

Vaxart: Differentiated Covid Oral Route Remains Viable

Nov 16

Vaxart: A Close Look At Their COVID-19 Oral Tablet Vaccine Program

Oct 30

Earnings and Revenue Growth Forecasts

NasdaqCM:VXRT - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202638-96-66-894
12/31/202530-89-58-764
12/31/202434-77-63-683
9/30/202417-72-51-51N/A
6/30/202414-76-62-62N/A
3/31/20249-82-68-67N/A
12/31/20237-82-72-70N/A
9/30/20234-89-92-86N/A
6/30/20232-101-93-86N/A
3/31/20231-108-104-94N/A
12/31/20220-108-104-95N/A
9/30/20220-105-88-81N/A
6/30/20220-93-87-81N/A
3/31/20220-80-74-68N/A
12/31/20211-70-65-60N/A
9/30/20211-64-60-55N/A
6/30/20211-54-54-50N/A
3/31/20212-47-39-37N/A
12/31/20204-32-25-24N/A
9/30/20208-25-17-17N/A
6/30/20208-22-12-12N/A
3/31/20207-19-12-12N/A
12/31/201910-19-14-13N/A
9/30/20198-17-16-15N/A
6/30/20198-18-17-16N/A
3/31/20198-22-10-9N/A
12/31/20184-18-15-15N/A
9/30/20183-15-12-11N/A
6/30/20184-12N/A-8N/A
3/31/20185-7N/A-16N/A
12/31/20176-12N/A-10N/A
9/30/20179-16N/A-9N/A
12/31/20168-19N/A-12N/A
12/31/20150-22N/A-15N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: VXRT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: VXRT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: VXRT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: VXRT's revenue (45.2% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: VXRT's revenue (45.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if VXRT's Return on Equity is forecast to be high in 3 years time


Discover growth companies